Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis
Posted inCardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.
Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents
Posted innews Pediatrics Public Health

Rare but Real: Higher Risks of Vascular and Inflammatory Disease After SARS‑CoV‑2 Infection Than After BNT162b2 Vaccination in Children and Adolescents

A nationwide English cohort study (n≈13.9M) found transient but significant increases in rare vascular and inflammatory events after first SARS‑CoV‑2 infection and a smaller, short-lived increase in myocarditis/pericarditis after first BNT162b2 vaccination—supporting vaccination to reduce greater risks from infection.